NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novo Nordisk A/S's revenue for the three months ended in Sep. 2015 was $4,032 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2015 was $15,832 Mil. Novo Nordisk A/S's revenue per share for the three months ended in Sep. 2015 was $1.57. Its revenue per share for the trailing twelve months (TTM) ended in Sep. 2015 was $6.11.
Novo Nordisk A/S has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Novo Nordisk A/S was 23.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 14.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 15.00% per year.
During the past 13 years, Novo Nordisk A/S's highest 3-Year average Revenue per Share Growth Rate was 127.60% per year. The lowest was -46.20% per year. And the median was 13.20% per year.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Novo Nordisk A/S Revenue for the trailing twelve months (TTM) ended in Sep. 2015 was 4073.66903614 (Dec. 2014 ) + 3654.61031992 (Mar. 2015 ) + 4071.47156184 (Jun. 2015 ) + 4032.08572246 (Sep. 2015 ) = $15,832 Mil.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Novo Nordisk A/S Annual Data
Novo Nordisk A/S Quarterly Data